All In Biotech

Drug Trial Radar · NCT07392372

A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV

A Phase I First-in-human Clinical Trial to Evaluate the Safety, Pharmacokinetics, and Antiviral Activity of the Broadly Neutralizing Antibody BNT351 in Adults Living Without and With HIV

Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

67

Planned (sponsor's estimate)

Start

Feb 9, 2026

Primary completion

Nov 2026

Study completion Jun 2027

Sponsor

Lead sponsor
BioNTech SEIndustry
Sponsor type
Industry
First posted
Feb 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will test the safety and blood levels of the antibody BNT351 in people living without and with human immunodeficiency virus (HIV). This study will also test the anti-viral activity of BNT351 in people living with HIV (PLWH) with detectable virus levels. The main goals of this study are: * To learn about the safety of BNT351 and check for side effects. * To measure the amount of BNT351 antibody in blood over time. * To test the amount of HIV in the blood at different times after treatment with BNT351 in people living with HIV.

Conditions

  • HIV -1 Infection

Interventions

  • BNT351Drug

    IV infusion

  • PlaceboDrug

    IV infusion

  • BNT351Drug

    SC injection

  • PlaceboDrug

    SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts A and B - Occurrence of at least one adverse event (AE)Time frame: From dosing to 56 days post-dose
  2. Parts A and B - Occurrence of at least one serious AE (SAE)Time frame: From dosing to 56 days post-dose
  3. Parts A and B (except for Cohort A1) - Occurrence of infusion-related reactions (IRRs) Grade ≥2 (graded based on National Cancer Institute Common Terminology Criteria for AEs [NCI CTCAE] version 5.0 as specified in the protocol)Time frame: From the start of IV dosing through 72 hours after the start of IV dosing
  4. Parts A and B - Occurrence of at least one solicited local reaction (pain/tenderness, erythema/redness, induration/swelling) at the investigational medicinal product administration siteTime frame: From dosing through 7 days post-dose
  5. Parts A and B- Occurrence of at least one solicited systemic event (vomiting, diarrhea, headache, fatigue/malaise, myalgia/arthralgia, fever)Time frame: From dosing through 7 days post-dose
  6. Parts A and B - Assessment of maximum concentration of BNT351Time frame: From dosing through 7 days post-dose
  7. Part B - Occurrence of any acquired immunodeficiency syndrome (AIDS)-defining illness or opportunistic infection as defined in the protocolTime frame: From dosing up to the time of cART initiation (up to a maximum of 56 days post-dose)
  8. Part B - Occurrence of absolute CD4+ T cell count <350 cells/µL or CD4+ T cell count <15% of total lymphocyte countTime frame: From dosing up to the time of cART initiation (up to a maximum of 56 days post-dose)
  9. Part B - Change from baseline in HIV log10 plasma viral load prior to cART initiationTime frame: At 7, 14, 21, 28, 35, 42, 49, and 56 days post-dose
  10. Part B - Maximum decrease from baseline in HIV log10 plasma viral load prior to cART initiationTime frame: From baseline up to the time of cART initiation (up to a maximum of 56 days post-dose)
  11. Part B - Time from dosing to lowest viral load prior to cART initiationTime frame: From dosing up to the time of cART initiation (up to a maximum of 56 days post-dose)
  12. Part B - Time from dosing to viral rebound defined as HIV-1 RNA viral load increase >0.75 log10 copies/mL from nadir (i.e., lowest HIV-1 RNA viral load from 7 days post-dose (Visit 3) and through pre-cART initiation)Time frame: From dosing up to the time of cART initiation (up to a maximum of 56 days post-dose)

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Cook County Health

    Chicago, Illinois · Recruiting

  • Johns Hopkins

    Baltimore, Maryland · Recruiting

  • Washington University

    St Louis, Missouri · Recruiting

  • Columbia University

    New York, New York · Recruiting

  • UK Köln

    Cologne, Germany · Recruiting

  • CRS Mannheim

    Mannheim, Germany · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.